Cargando…
Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
There is a lack of useful biomarkers for predicting the efficacy of anti–programmed death-1 (PD-1) therapy for advanced gastric and colorectal cancer. To address this issue, in this study we investigated the correlation between inflammatory marker expression and survival in patients with advanced ga...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005614/ https://www.ncbi.nlm.nih.gov/pubmed/33791296 http://dx.doi.org/10.3389/fcell.2021.638312 |
_version_ | 1783672146446254080 |
---|---|
author | Fan, Xiaona Wang, Dan Zhang, Wenjing Liu, Jinshuang Liu, Chao Li, Qingwei Ma, Zhigang Li, Hengzhen Guan, Xin Bai, Yibing Yang, Jiani Lou, Changjie Li, Xiaobo Wang, Guangyu Li, Zhiwei |
author_facet | Fan, Xiaona Wang, Dan Zhang, Wenjing Liu, Jinshuang Liu, Chao Li, Qingwei Ma, Zhigang Li, Hengzhen Guan, Xin Bai, Yibing Yang, Jiani Lou, Changjie Li, Xiaobo Wang, Guangyu Li, Zhiwei |
author_sort | Fan, Xiaona |
collection | PubMed |
description | There is a lack of useful biomarkers for predicting the efficacy of anti–programmed death-1 (PD-1) therapy for advanced gastric and colorectal cancer. To address this issue, in this study we investigated the correlation between inflammatory marker expression and survival in patients with advanced gastric and colorectal cancer. Data for 111 patients with advanced gastric and colorectal cancer treated with anti–PD-1 regimens were retrospectively analyzed. Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and clinical characteristics of each patient were selected as the main variables. Overall response rate, disease control rate, and progression-free survival were primary endpoints, and overall survival and immune-related adverse events (irAEs) were secondary endpoints. The chi-squared test and Fisher’s exact test were used to evaluate relationships between categorical variables. Uni- and multivariate Cox regression analyses were performed, and median progression-free survival and overall survival were estimated with the Kaplan–Meier method. The overall response rate and disease control rate of anti–PD-1therapy in advanced gastric and colorectal tumors were 12.61 and 66.66%, respectively. The patients with MLR < 0.31, NLR < 5, and PLR < 135 had a significantly higher disease control rate than those with MLR > 0.31, NLR > 5, and PLR > 135 (P < 0.05). The multivariate analysis revealed that MLR < 0.31, BMI > 18.5, and anti–PD-1 therapy in first-line were associated with prolonged PFS. MLR < 0.31 and BMI > 18.5 were associated with prolonged overall survival. The irAE rate differed significantly between PLR groups, and PLR < 135 was associated with an increased rate of irAEs (P = 0.028). These results indicate that the inflammatory markers NLR, MLR, and PLR have clinical utility for predicting survival or risk of irAEs in patients with advanced gastric cancer and colorectal cancer. |
format | Online Article Text |
id | pubmed-8005614 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80056142021-03-30 Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy Fan, Xiaona Wang, Dan Zhang, Wenjing Liu, Jinshuang Liu, Chao Li, Qingwei Ma, Zhigang Li, Hengzhen Guan, Xin Bai, Yibing Yang, Jiani Lou, Changjie Li, Xiaobo Wang, Guangyu Li, Zhiwei Front Cell Dev Biol Cell and Developmental Biology There is a lack of useful biomarkers for predicting the efficacy of anti–programmed death-1 (PD-1) therapy for advanced gastric and colorectal cancer. To address this issue, in this study we investigated the correlation between inflammatory marker expression and survival in patients with advanced gastric and colorectal cancer. Data for 111 patients with advanced gastric and colorectal cancer treated with anti–PD-1 regimens were retrospectively analyzed. Neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and clinical characteristics of each patient were selected as the main variables. Overall response rate, disease control rate, and progression-free survival were primary endpoints, and overall survival and immune-related adverse events (irAEs) were secondary endpoints. The chi-squared test and Fisher’s exact test were used to evaluate relationships between categorical variables. Uni- and multivariate Cox regression analyses were performed, and median progression-free survival and overall survival were estimated with the Kaplan–Meier method. The overall response rate and disease control rate of anti–PD-1therapy in advanced gastric and colorectal tumors were 12.61 and 66.66%, respectively. The patients with MLR < 0.31, NLR < 5, and PLR < 135 had a significantly higher disease control rate than those with MLR > 0.31, NLR > 5, and PLR > 135 (P < 0.05). The multivariate analysis revealed that MLR < 0.31, BMI > 18.5, and anti–PD-1 therapy in first-line were associated with prolonged PFS. MLR < 0.31 and BMI > 18.5 were associated with prolonged overall survival. The irAE rate differed significantly between PLR groups, and PLR < 135 was associated with an increased rate of irAEs (P = 0.028). These results indicate that the inflammatory markers NLR, MLR, and PLR have clinical utility for predicting survival or risk of irAEs in patients with advanced gastric cancer and colorectal cancer. Frontiers Media S.A. 2021-03-15 /pmc/articles/PMC8005614/ /pubmed/33791296 http://dx.doi.org/10.3389/fcell.2021.638312 Text en Copyright © 2021 Fan, Wang, Zhang, Liu, Liu, Li, Ma, Li, Guan, Bai, Yang, Lou, Li, Wang and Li. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Fan, Xiaona Wang, Dan Zhang, Wenjing Liu, Jinshuang Liu, Chao Li, Qingwei Ma, Zhigang Li, Hengzhen Guan, Xin Bai, Yibing Yang, Jiani Lou, Changjie Li, Xiaobo Wang, Guangyu Li, Zhiwei Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy |
title | Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy |
title_full | Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy |
title_fullStr | Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy |
title_full_unstemmed | Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy |
title_short | Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy |
title_sort | inflammatory markers predict survival in patients with advanced gastric and colorectal cancers receiving anti–pd-1 therapy |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005614/ https://www.ncbi.nlm.nih.gov/pubmed/33791296 http://dx.doi.org/10.3389/fcell.2021.638312 |
work_keys_str_mv | AT fanxiaona inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT wangdan inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT zhangwenjing inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT liujinshuang inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT liuchao inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT liqingwei inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT mazhigang inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT lihengzhen inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT guanxin inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT baiyibing inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT yangjiani inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT louchangjie inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT lixiaobo inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT wangguangyu inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy AT lizhiwei inflammatorymarkerspredictsurvivalinpatientswithadvancedgastricandcolorectalcancersreceivingantipd1therapy |